Home Blog Page 267

Summer Sleep Comfort, Prime Savings: Breescape is offering up to 50% for June Prime Day Deals

By
Advertorial Desk
-

NEW YORK, June 23, 2026 /PRNewswire/ — As sweltering summer nights arrive and restless hot sleepers struggle to beat nighttime heat, Breescape delivers a refreshing solution for all-night cool, comfortable rest.


Breescape, the bedding brand dedicated to providing uninterrupted cooling comfort for hot sleepers, is making it easier than ever to upgrade your sleep setup just in time for the peak summer season. Trusted by Ashley Graham, model, body advocate, and Breescape Brand Partner, Breescape is offering shoppers Prime Day savings on its refreshing cooling bedding, the perfect way to stay comfortably cool throughout the night.

Prime Day Deals:

Get up to 50% on Breescape’s Prime Day selection

  • Breescape Cooling Comforter Blanket – Up to 50% off: Engineered for lightweight comfort, its fresh yet cozy feel uses advanced cooling fibers to regulate temperature and wick away moisture, while its dual-sided feature allows users to pick the side that works best for them. Perfect for hot sleepers or anyone who wants a breathable, cloud-like layer without sacrificing warmth.
  • Breescape Cooling Sheets – Up to 40% off: Indulge in the rest you deserve with these ultra-soft, moisture-wicking sheets designed to stay cool to the touch and breathable all night long. The smooth finish and tailored fit make the perfect touch of luxury to any bedroom revamp. Upgraded choice available with built-in pockets to keep your essentials neatly stored within reach.
  • Breescape Cooling Mattress Topper – Up to 40% off: This 3-inch ventilated topper features BlendTek™ cooling, responsive foam, and anti-slip straps, transforming any mattress into a haven of full-body support, coolness, and breathability—ideal for those plagued by heat-trapping mattress surfaces, nighttime aches, or shifting bedding.
  • Breescape Cooling Pillowcases – Up to 35% off: Complete your cooling setup with pillowcases that stay breathable and crisp in every season so you can drift off without flipping your pillow to the “cold side.” Designed for Gentle Hair Care, the smooth texture helps prevent tangling and frizz, elevating your overnight routine to give your bedroom a seasonal refresh that feels as good as it looks.

Cooling comfort is essential for a good nights’ sleep. Breescape cooling products are engineered to maintain balanced temperature and deliver superior sleep quality. Don’t miss the opportunity to make this your the most refreshed summer yet. All Breescape Prime Day deals will be exclusively available at Amazon. Visit Amazon.com/breescape for more information.

About Breescape

Breescape® is a sleep science-led brand engineered for hot sleepers, offering the ultimate solution for a refreshing, sweat-free sleep experience, even during the hottest months of the year. Our patented fabric technology, BlendTek™, blends multiple fibers in the golden ratio to deliver real, long-lasting coolness with an instant cool-to-the-touch sensation, enhanced breathability, and efficient moisture-wicking for sleepers experiencing hot flashes, ensuring all-night comfort.

For more information, visit www.breescape.com or shop at Amazon.com/breescape. Connect with Breescape on social media @Breescapehome.

Double Award Victory! AISpeech’s MA600D Wins ‘Best of Show’ at Infocomm, Adding to ISE Triumph

By
Advertorial Desk
-

The article is from Shuzhi Society

LAS VEGAS, June 22, 2026 /PRNewswire/ — June 18, 2026, following its success at ISE 2026 in Barcelona, AISpeech’s flagship product, the Matrix Array Microphone MA600D, has once again passed the rigorous selection of the professional audiovisual industry’s most authoritative judging panel, claiming a “Best of Show” award at Infocomm 2026 in Las Vegas. This dual recognition across two continents and two distinct evaluation systems underscores that AISpeech’s AI-driven audio technology has firmly established itself as a leading force in the Pro AV industry.

Double Award Victory! AISpeech’s MA600D Wins ‘Best of Show’ at Infocomm, Adding to ISE Triumph
Double Award Victory! AISpeech’s MA600D Wins ‘Best of Show’ at Infocomm, Adding to ISE Triumph

The “Best of Show” award, organized by Infocomm’s partner media and independent experts, honors products with outstanding innovation, scenario adaptability, and user value. The MA600D stood out among hundreds for acoustic performance, ease of deployment, AI integration, and market differentiation.

Throughout the show, AISpeech’s booth (C8787) attracted a steady stream of integrators and acoustic consultants from North America, Latin America, many of whom returned multiple times to experience the MA600D in live demonstrations. One senior U.S. Pro AV integrator commented, “I’ve seen many ‘AI microphones,’ but the MA600D is the first product that makes background noise completely unnoticeable to remote listeners in a real-world noisy exhibition hall.” This honor not only validates the product’s technological leadership but also strengthens AISpeech’s global market position as an “AI acoustic enabler.”

AI Acoustic DNA — Built for Hybrid Collaboration

At the heart of the MA600D’s award-winning performance is AISpeech’s proprietary ClearSpeakAI algorithm. It intelligently tackles four persistent audio pain points in hybrid work:

AI Noise Reduction: Dynamically identifies and suppresses over 300 types of environmental noise (such as keyboard clicks and air conditioner hum…), preserving only natural, rich human voice.

AI Dereverberation: Adaptively eliminates flutter echoes and excessive reflections common in glass-walled rooms or small meeting spaces, ensuring clear speech even in complex acoustic environments.

AI Echo Cancellation: Enables full-duplex, uninterrupted conversation, allowing both local and remote participants to speak naturally at the same time.

AI Automatic Gain Control: Continuously tracks speaker distance and head movement, maintaining consistent output volume whether the presenter stands, walks, or leans back in a chair.

AI Empowerment — Redefining the Boundaries of Spatial Audio

The “Best of Show” awards at ISE and Infocomm are the two most prestigious global honors in Pro AV. AISpeech’s double win not only proves product excellence across different regions but also signals a clear trend: the Pro AV market is shifting from hardware specs to AI‑driven, context‑adaptive intelligence. During the show, AISpeech reached cooperation intentions with system integrators from many countries and will continue to deepen collaboration in high‑value scenarios like multinational video conferencing, large roundtables, and cross‑site collaborative offices.

Double Award Victory! AISpeech’s MA600D Wins ‘Best of Show’ at Infocomm, Adding to ISE Triumph

By
Advertorial Desk
-

The article is from Shuzhi Society

LAS VEGAS, June 22, 2026 /PRNewswire/ — June 18, 2026, following its success at ISE 2026 in Barcelona, AISpeech’s flagship product, the Matrix Array Microphone MA600D, has once again passed the rigorous selection of the professional audiovisual industry’s most authoritative judging panel, claiming a “Best of Show” award at Infocomm 2026 in Las Vegas. This dual recognition across two continents and two distinct evaluation systems underscores that AISpeech’s AI-driven audio technology has firmly established itself as a leading force in the Pro AV industry.

Double Award Victory! AISpeech’s MA600D Wins ‘Best of Show’ at Infocomm, Adding to ISE Triumph
Double Award Victory! AISpeech’s MA600D Wins ‘Best of Show’ at Infocomm, Adding to ISE Triumph

The “Best of Show” award, organized by Infocomm’s partner media and independent experts, honors products with outstanding innovation, scenario adaptability, and user value. The MA600D stood out among hundreds for acoustic performance, ease of deployment, AI integration, and market differentiation.

Throughout the show, AISpeech’s booth (C8787) attracted a steady stream of integrators and acoustic consultants from North America, Latin America, many of whom returned multiple times to experience the MA600D in live demonstrations. One senior U.S. Pro AV integrator commented, “I’ve seen many ‘AI microphones,’ but the MA600D is the first product that makes background noise completely unnoticeable to remote listeners in a real-world noisy exhibition hall.” This honor not only validates the product’s technological leadership but also strengthens AISpeech’s global market position as an “AI acoustic enabler.”

AI Acoustic DNA — Built for Hybrid Collaboration

At the heart of the MA600D’s award-winning performance is AISpeech’s proprietary ClearSpeakAI algorithm. It intelligently tackles four persistent audio pain points in hybrid work:

AI Noise Reduction: Dynamically identifies and suppresses over 300 types of environmental noise (such as keyboard clicks and air conditioner hum…), preserving only natural, rich human voice.

AI Dereverberation: Adaptively eliminates flutter echoes and excessive reflections common in glass-walled rooms or small meeting spaces, ensuring clear speech even in complex acoustic environments.

AI Echo Cancellation: Enables full-duplex, uninterrupted conversation, allowing both local and remote participants to speak naturally at the same time.

AI Automatic Gain Control: Continuously tracks speaker distance and head movement, maintaining consistent output volume whether the presenter stands, walks, or leans back in a chair.

AI Empowerment — Redefining the Boundaries of Spatial Audio

The “Best of Show” awards at ISE and Infocomm are the two most prestigious global honors in Pro AV. AISpeech’s double win not only proves product excellence across different regions but also signals a clear trend: the Pro AV market is shifting from hardware specs to AI‑driven, context‑adaptive intelligence. During the show, AISpeech reached cooperation intentions with system integrators from many countries and will continue to deepen collaboration in high‑value scenarios like multinational video conferencing, large roundtables, and cross‑site collaborative offices.

Ucore Produces NdPr Oxide and Ships Qualification Samples to Major Rare Earth Magnet Manufacturers

By
Advertorial Desk
-

Ucore announces:

  • Ucore has produced 99.5%+ neodymium-praseodymium oxide generated at its 52-stage RapidSX™ Demonstration Plant in Kingston, Ontario
  • Initial NdPr oxide qualification samples were shipped to major rare earth permanent magnet manufacturers serving North American and European supply chains
  • Testing of the samples begin the process of confirming purity, phase composition, consistency, and compatibility with customer-compliant NdFeB permanent magnet manufacturing processes
  • The qualification work is intended to support the development of structured definitive supply agreements aligned with Ucore’s planned Louisiana Strategic Metals Complex and its Commercialization and Demonstration Facility in Kingston, Ontario

Halifax, Nova Scotia–(Newsfile Corp. – June 22, 2026) – Ucore Rare Metals Inc. (TSXV: UCU) (OTCQX: UURAF) (“Ucore” or the “Company“) is pleased to announce that it has produced commercial-grade neodymium-praseodymium (“NdPr“) oxide and shipped initial qualification samples to major rare earth permanent magnet manufacturers for technical evaluation.

The sample shipments mark an important step in Ucore’s strategy to connect its RapidSX™ rare earth separation platform directly with downstream magnet, metal, alloy, and advanced materials supply chains. NdPr oxide is a critical midstream material that is converted into metal and alloy feedstock for neodymium-iron-boron (“NdFeB“) permanent magnets, which are used across high-performance motors, robotics, electric vehicles, industrial automation, renewable energy systems, and defense applications.

The NdPr oxide qualification samples were produced as part of Ucore’s ongoing demonstration and commercialization work. During this work, the Company’s 52-stage RapidSX™ Demonstration Plant at its Commercialization and Demonstration Facility (“CDF“) in Kingston, Ontario, processed a heavy mixed rare earth oxide (“MREO“) feedstock derived from an ionic clay source and produced 99.5%+ NdPr chloride. Ucore subsequently converted a portion of this chloride solution into 99.5%+ NdPr oxide.

Strategic Alignment with Western Supply Chain Development

Ucore has previously announced strategic relationships with major rare earth permanent magnet manufacturers that are working to expand Western magnet production capacity. These relationships are intended to position Ucore as a midstream rare earth oxide supplier for strategically important downstream manufacturers focused on rebuilding North American and allied rare earth magnet supply chains. In addition to utilizing dysprosium (“Dy”) and terbium (“Tb”), which Ucore plans to produce in Louisiana, these magnet manufacturers also utilize NdPr oxide, which is expected to be an important part of Ucore’s product suite at its prospective Louisiana SMC.

“Sample qualification is a critical step toward developing potential offtake arrangements,” stated Pat Ryan, P.Eng., Ucore’s Chairman and Chief Executive Officer. “The NdPr oxide shipped to major rare earth magnet manufacturers was not produced in a concept study. It was produced through Ucore’s RapidSX™ demonstration platform, from real mixed rare earth feedstock, and is now in the hands of companies working to develop Western magnet manufacturing capacity.”

Mike Schrider, P.E., Ucore’s Vice President and Chief Operating Officer, commented: “For downstream customers, oxide quality matters. Purity, impurity control, physical form, consistency, conversion performance, and traceability all have to be understood before commercial supply can begin. These samples give potential customers the material they need to evaluate Ucore’s rare earth oxides against their own technical and manufacturing requirements.”

Schrider added: “This work also gives Ucore direct feedback from downstream customers as we continue to translate the learnings from our Kingston CDF into the design, construction, commissioning, and operational plans of the Louisiana Strategic Metals Complex.”

Customer Qualification: Turning Separated Oxides into Supply Chain Inputs

The evaluation work by major downstream customers focuses on confirming that Ucore’s rare earth oxides meet the technical, quality, and traceability requirements for use in Western magnet and advanced materials supply chains.

The qualification process is expected to include:

  • independent chemical assay work to confirm rare earth oxide purity and key impurity levels;
  • confirmation of oxide characteristics, including phase composition, handling, moisture, and consistency;
  • assessment of compatibility with magnet manufacturing requirements, including alloy formulation, process qualification, and finished magnet compliance expectations; and
  • development of product specifications, quality assurance protocols, logistics requirements, and commercial terms to support definitive long-term supply agreements.

This qualification process is a key step toward elevating strategic relationships currently at the MOU level and could contribute toward potential commercial offtake arrangements. It allows downstream manufacturers and advanced materials customers to certify that Ucore’s separated rare earth oxide products meet their required technical specifications before larger-volume supply commitments are finalized.

# # #

About Ucore Rare Metals Inc.
Ucore is focused on rare- and critical-metal resources, extraction, beneficiation, and separation technologies with the potential for production, growth, and scalability. Ucore’s vision and plan is to become a leading advanced technology company, providing best-in-class metal separation products and services to the mining and mineral extraction industry.

Through strategic partnerships, Ucore aims to support the development of a more diversified and resilient North American REE supply chain through the near-term development of a heavy and light rare-earth processing facility in the US State of Louisiana, subsequent SMCs in Canada and Alaska and the longer-term development of Ucore’s 100% controlled Bokan-Dotson Ridge Rare Heavy REE Project on Prince of Wales Island in Southeast Alaska, USA (“Bokan“).

Ucore is listed on the TSXV under the trading symbol “UCU” and in the United States on the OTC Markets’ OTCQX® Best Market under the ticker symbol “UURAF.”

For further information, please visit www.ucore.com.

Forward-Looking Statements

This press release contains “forward-looking information” and “forward-looking statements” (collectively “forward-looking statements” within the meaning of applicable Canadian securities laws. All statements in this release (other than statements of historical facts) that address future business development, technological development and/or acquisition activities (including any related required financings), timelines, events, products to be produced at the Louisiana SMC, or developments that the Company is pursuing are forward-looking statements. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance or results, and actual results or developments may differ materially from those in forward-looking statements.

For additional risks and uncertainties regarding the Company, its business activities, its ability to qualify for and receive any additional funding from any U.S. or Canadian government, the CDF and the aforementioned projects (generally), see the risk disclosure in the Company’s MD&A for Q1-2026 (filed on SEDAR+ on May 29, 2026) (www.sedarplus.ca) as well as the risks described below.

Regarding the disclosure above in the “About Ucore Rare Metals Inc.” section, the Company has assumed that it will be able to procure or retain additional partners and/or suppliers, in addition to Innovation Metals Corp. (“IMC“), as suppliers for Ucore’s expected future SMCs. Ucore has also assumed that sufficient external funding will be found to continue and complete the ongoing research and development work required at the CDF and also later prepare a new National Instrument 43-101 technical report that demonstrates that Bokan is feasible and economically viable for the production of both REE and co-product metals and the then prevailing market prices based upon assumed customer offtake agreements. Ucore has also assumed that sufficient external funding will be secured to continue the development of the specific engineering plans for the SMCs and their construction and eventual commissioning and operations.

Forward-looking statements are based on a number of material assumptions, including, without limitation: the successful completion and accuracy of baseline, front-end-engineering design and detailed engineering studies; the ability to complete further engineering, procurement, and construction activities as currently contemplated; the availability, cost, and timely delivery of equipment, materials, utilities, labour and construction services; the Company’s ability to secure sufficient financing on acceptable terms; the receipt and timing of all required permits and approvals; the successful scale-up and commercial deployment of RapidSX™ technology from demonstration to commercial operation; the availability of qualified feedstock from third-party suppliers; successful customer qualification and offtake discussions; continued support from governmental partners; and general economic, market, and industry conditions, including assumptions regarding rare earth oxide prices, which are subject to significant volatility..

Although the Company believes that the assumptions underlying the forward-looking information are reasonable, there can be no assurance that such assumptions will prove to be accurate or that the anticipated results, performance, or achievements will be realized. Actual results may differ materially from those expressed or implied by the forward-looking information.

Factors that could cause actual results to differ materially include, without limitation: risks associated with the development, scale-up, and commercialization of new or unproven technologies; the risk that RapidSX™ may not perform at commercial scale as expected; engineering design changes; inaccuracies in capital or operating cost estimates; cost escalation due to inflation, supply chain disruption, or market conditions; delays or failures in procurement, construction, or commissioning; the inability to obtain or maintain required permits, approvals, or regulatory authorizations; challenges in securing adequate financing; adverse capital market conditions; variability in feedstock supply, quality, or pricing; failure to secure or maintain commercial relationships, customer qualification, or offtake arrangements; fluctuations and uncertainty in rare earth oxide prices and demand; the risk that indicative or quoted market prices, including for ex-China markets, may not be realized; operational risks once in production, including equipment failures or lower-than-expected recoveries; geopolitical risk; changes in applicable laws or regulations; environmental or permitting challenges; loss of key personnel; and general economic, business, or competitive conditions.

Neither the TSXV nor its Regulation Services Provider (as that term is defined by the TSXV) accept responsibility for the adequacy or accuracy of this release.

CONTACTS

Michael Schrider, P.E., Ucore Vice President and Chief Operating Officer, is responsible for the content of this news release and may be contacted at 1.902.482.5214.

For additional information, please contact:

Mark MacDonald
Vice President, Investor Relations
Ucore Rare Metals Inc.
1.902.482.5214
mark@ucore.com

The issuer is solely responsible for the content of this announcement.

About Ucore Rare Metals Inc.

AS Watson Launches brand lab to Turn Retail Scale into a Data-driven Brand Growth Engine

By
Advertorial Desk
-

HONG KONG SAR – Media OutReach Newswire – 22 June 2026 – AS Watson Group has launched AS Watson brand lab, a data-driven brand creation and scaling platform designed to systematically identify, develop, and grow brands across its global retail ecosystem. Built on the company’s integrated O+O (Offline plus Online) capabilities, extensive distribution network, and deep consumer insight from over 180 million loyalty members, the platform transforms how brands are brought to market – enabling both the creation of new propositions and the rapid scaling of brands across multiple markets with speed, discipline and consistency.

AS Watson Launches brand lab to Turn Retail Scale into a Data-driven Brand Growth Engine

The initiative formalises capabilities the Group has been building internally, combining data-led demand identification, integrated distribution, and execution across more than 17,000 O+O stores in Asia and Europe.

Over the past two years, AS Watson has introduced more than 4,800 new brands and brand extensions across its network, underscoring the scale of its brand development activity.

From Incubation to Execution

AS Watson brand lab departs from traditional incubator models by embedding brand development directly within AS Watson’s retail ecosystem.

Rather than incubating brands ahead of their market entry, the platform operates inside the market, using real-time customer data, shopping behaviour and category dynamics to inform development decisions.

Dr Malina Ngai, Group CEO of AS Watson, said the model reflects the company’s structural advantage. “We don’t wait for brands to find the market – we build them where demand already exists, and scale them through our ecosystem.”

A Systemised Growth Model

At the core of AS Watson brand lab is an integrated operating model linking insight, creation, distribution, demand activation and scaling.

The platform leverages AS Watson’s over 180 million loyalty members and O+O capabilities to accelerate brand selection and commercial execution.

A Structured Pathway to Scale

Brands within AS Watson brand lab are supported through a structured growth pathway, progressing from early-stage validation to regional scaling and category leadership.

At each stage, brands receive differentiated support across insight, distribution, marketing activation and investment, ensuring resources are focused where the greatest growth potential exists.

This staged approach enables AS Watson to systematically build, scale and prioritise brands, improving success rates while maintaining disciplined capital allocation.

Focus on High-Growth Segments

AS Watson brand lab will prioritise product segments including Asian beauty trends (K-beauty, J-beauty, C-beauty), ingredient-led skincare, health and wellness products and elevated personal care – areas where consumer demand continues to evolve rapidly.

The Group expects the platform to strengthen its ability to build proprietary and exclusive brands while improving speed-to-market and capital efficiency.

Proven Brand Scaling in Action

Early outcomes demonstrate how AS Watson brand lab translates insight into accelerated growth – not only by shaping brand development, but by scaling brands rapidly across markets through its integrated O+O ecosystem.

Across multiple categories and geographies, the platform has enabled brands to move from targeted market entry to multi-market expansion with speed and discipline:

COSRX (K-Beauty)– By combining COSRX’s innovation-led skincare expertise with
AS Watson’s extensive retail footprint and deep consumer insights, the partnership has accelerated international expansion and broadened consumer reach. This illustrates how the platform converts strong brand propositions into sustained category growth across markets.

&honey (J-Beauty) – Leveraging its distinctive product positioning alongside
AS Watson’s regional scale, &honey rapidly expanded beyond its home market, rolling out across multiple Asian markets within a short timeframe. This demonstrates the platform’s ability to systematically scale proven domestic leaders into regional brands.

e.l.f. Cosmetics (US) – Through partnership with AS Watson, e.l.f. has extended its community-led, value-driven model across Europe, translating strong brand engagement into measurable market penetration. The example highlights how consumer-centric brands can be amplified through local market execution at scale.

essence (Germany) – The expansion of essence across multiple markets, including exclusive partnerships, reflects how purpose-driven brands can achieve consistency and reach when supported by integrated distribution and retail insight. This underscores the platform’s ability to build sustained brand relevance and loyalty across diverse markets.

Across these examples, brands have scaled through a consistent model – combining data-led selection, integrated distribution, and coordinated market execution – demonstrating how AS Watson brand lab functions as a repeatable engine for brand growth, from market entry through to regional scale.

Scaling a Repeatable Engine

AS Watson brand lab positions AS Watson to leverage its retail footprint not only as a distribution channel, but as an engine for brand creation and scaling.

The initiative signals a shift from opportunistic brand sourcing towards a structured, repeatable growth model, reinforcing AS Watson’s ability to scale brands with speed, discipline and consistency while driving long-term portfolio value.

AS Watson continues to engage with selected brand partners and emerging brands aligned with its focus areas, with further information available through its official
AS Watson brand lab platform (https://www.aswatson.com/asw-brand-lab)

Hashtag: #ASWatson

The issuer is solely responsible for the content of this announcement.

About AS Watson Group

Established in 1841, AS Watson Group is one of the world’s longest-standing and most recognised retail companies with roots in Asia. Today, the company operates over 17,000 stores across 12 retail brands in 31 markets, employing 130,000 people globally. This makes AS Watson Group the largest international health and beauty retailer in the world.

In the fiscal year 2025, AS Watson Group reported revenue of over US$26 billion. The company’s technology-enabled O+O (Offline plus Online) platforms serve over 6 billion shoppers annually, seamlessly integrating physical and digital retail experiences.

AS Watson Group supported over 180 charitable and non-profit organisations every year, dedicating over 40,000 hours of volunteer work to serve over 370,000 people in need in our operating markets.

AS Watson Group is also a member of the world-renowned multinational conglomerate CK Hutchison Holdings Limited, which has four core businesses – ports and related services, retail, infrastructure and telecommunications in over 50 countries.

Please visit for more information.

RZOLV Technologies Completes NRC IRAP-Supported R&D Project for Non-Cyanide Gold Extraction Technology

By
Advertorial Desk
-
Vancouver, British Columbia – Newsfile Corp. – June 22, 2026 – RZOLV Technologies Inc. (TSXV: RZL) (OTCQB: RZOLF) (FSE: S711) (“RZOLV” or the “Company”) is pleased to announce that its wholly owned operating subsidiary, Innovation Mining Inc. (“Innovation Mining”), has completed its first research and development project supported by the National Research Council of Canada Industrial Research Assistance Program (“NRC IRAP”).

Innovation Mining received advisory services and funding from NRC IRAP to support a research and development project focused on the Company’s proprietary RZOLV™ non-cyanide gold extraction technology. The completed work included bench-scale evaluation of electrochemical regeneration, reagent-management approaches, and process-control conditions intended to inform future closed-loop testing and pilot-scale evaluation. The project generated internal technical information to support continued process development but did not include commercial-scale demonstration or a determination of commercial performance.

The Company believes completion of the project has strengthened its internal technical capacity and provided additional bench-scale development information to support further evaluation of the RZOLV technology platform.

As a result of the project, the Company has expanded its internal technical capabilities through the addition of two full-time employees to its laboratory team. The Company believes this strengthened in-house capacity will support continued research and development, process optimization, and future scale-up activities.

The Company acknowledges the support of NRC IRAP. Hanif Jafari, Chief Technology Officer of RZOLV Technologies, commented: “The completion of this project was valuable for our team as it allowed the Company to carry out focused bench-scale development work while also expanding our laboratory capabilities through the addition of two full-time technical employees. We are grateful to NRC IRAP for its support and for the guidance provided during the project. We look forward to building on this work through further technical evaluation and development of the RZOLV platform.”

The Company intends to continue development work through Innovation Mining, including further technical validation, process optimization, pilot-scale activities, and strategic commercial engagement related to the RZOLV technology platform.

About NRC IRAP

The National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) supports the growth of innovative Canadian small and medium-sized businesses by providing advisory services, connections and financial assistance. NRC IRAP helps Canadian companies strengthen their technical and innovation capabilities, address business and technology challenges, and advance innovative products and services toward the marketplace.

About RZOLV Technologies Inc.

RZOLV Technologies Inc. is a clean technology company focused on the development and commercialization of alternatives to conventional cyanide-based gold extraction. Through its wholly owned operating subsidiary, Innovation Mining Inc., the Company is advancing its proprietary RZOLV™ technology, a non-cyanide, water-based gold extraction technology under development, designed to reduce reliance on cyanide-based processing in applicable mining applications.

Neither TSX Venture Exchange nor its Regulation Services Provider, as that term is defined in policies of the TSX Venture Exchange, accepts responsibility for the adequacy or accuracy of this release.

For further information, please contact:

Duane Nelson
President & CEO
RZOLV Technologies Inc.
Tel: +1-604-332-2662
Email: duane@rzolv.com

Forward-Looking Statements

This news release contains forward-looking statements and forward-looking information within the meaning of applicable Canadian securities laws. Forward-looking statements in this release include, but are not limited to, statements regarding continued research and development, future technical validation, process optimization, pilot-scale activities, scale-up activities, strategic commercial engagement, potential commercialization, and the future advancement of the RZOLV technology platform.

Forward-looking statements are based on assumptions that management considers reasonable as of the date of this news release, including assumptions regarding the availability of funding, personnel, laboratory and pilot-scale equipment, technical data, third-party testing and validation resources, commercial partner interest, regulatory and environmental assessment requirements, and the Company’s ability to continue advancing its technology platform.

Actual results may differ materially from those expressed or implied by forward-looking statements due to risks and uncertainties, including risks related to technology development, scale-up from laboratory testing to pilot-scale and commercial applications, reagent consumption, electrochemical regeneration performance, process-control requirements, environmental and regulatory considerations, availability of capital, availability of qualified personnel, intellectual property protection, third-party validation, commercial partner adoption, market acceptance, and general business, economic and capital market conditions.

Readers are cautioned not to place undue reliance on forward-looking statements. The Company undertakes no obligation to update or revise any forward-looking statements, except as required by applicable law.

Hashtag: #RZOLVTechnologiesInc

The issuer is solely responsible for the content of this announcement.

CARsgen Announces Approval of Satri-cel, the World’s First CAR T-Cell Therapy Product for Solid Tumors

By
Advertorial Desk
-

SHANGHAI, June 22, 2026 /PRNewswire/ — CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced that as informed by the National Medical Products Administration (“NMPA”) today, the New Drug Application (“NDA”) of satricabtagene autoleucel (“satri-cel”), the proprietary autologous humanized Claudin18.2 CAR T-cell therapy product, was approved for the treatment of patients with Claudin18.2-positive, HER2-negative advanced gastric/ gastroesophageal junction adenocarcinoma (G/GEJA) who have failed at least two prior lines of therapy. Satri-cel is the world’s first approved CAR T-cell therapy product for the treatment of solid tumors.

Gastric cancer is one of the malignancies with the highest disease burden worldwide, ranking fifth in both incidence and mortality globally, with approximately 970,000 new cases and 660,000 deaths annually [1]. More than 70% of new and fatal cases occur in Asia [2], and Chinese patients account for approximately 47% of the global gastric cancer burden [3]. According to statistics from the National Cancer Center of China, there were approximately 360,000 new cases and 260,000 deaths from gastric cancer in China in 2022, ranking fifth in cancer incidence and third in cancer-related mortality [4]. Despite continuous advances in surgical techniques and comprehensive treatment modalities, gastric cancer is insidious in onset. In China, the proportion of early-stage gastric cancer diagnosis remains below 20%, and the 5-year survival rate for advanced gastric cancer is only about 10% [5]. Gastric cancer is characterized by high incidence, low early diagnosis rate, high heterogeneity, and high mortality. Conventional chemotherapy drugs have reached a plateau, targeted therapy options are limited, and the proportion and magnitude of benefit from immunotherapy still urgently need to be improved. Therefore, patients with unresectable or metastatic gastric cancer still face substantial unmet medical needs, and there is an urgent demand to drive the discovery and exploration of more precision therapies and novel anti-tumor agents.

Claudin18.2 is a highly selective marker protein. Its expression in normal healthy tissues is very limited, occurring only in differentiated gastric mucosal epithelial cells, whereas it is highly expressed in gastric cancer and other malignant tumors. Satri-cel is an autologous CAR-T cell product targeting Claudin18.2. It is genetically modified to express a CAR construct consisting of a humanized Claudin18.2-specific single-chain monoclonal antibody fragment (hu8E5-2I), a CD8α hinge region, a CD28 transmembrane region, a CD28 intracellular signaling domain (CD28 ICD), and a CD3ζ intracellular signaling region. To our knowledge, we were the first in the world to successfully identify, validate, and report the solid tumor-associated antigen Claudin18.2 as a valid target for CAR T-cell therapy. To further address the challenges of the tumor microenvironment in treating solid tumors, the company independently developed an innovative, patent-protected preconditioning regimen which is to be administered prior to infusion of satri-cel. This regimen features the addition of low-dose nab-paclitaxel to the conventional lymphodepletion regimen comprising cyclophosphamide and fludarabine to enhance the infiltration and anti-tumor efficacy of CAR T cells. The Company has implemented global patent layout around satri-cel, covering the target, indications, dosage, and preconditioning regimens, among others.

The clinical efficacy of satri-cel has received authoritative recognition from top international medical journals. The results of its confirmatory randomized controlled study have been published in The Lancet [6]. Clinical data show that among patients with advanced, heavily pretreated G/GEJ cancer who have extremely limited treatment options and a very poor prognosis, satri-cel demonstrated significant efficacy benefit and a good safety profile compared to existing treatments, bringing a new treatment option to patients with advanced gastric cancer. This major breakthrough not only establishes a new standard for CAR-T therapy in solid tumors but also lays a solid scientific foundation for advancing to earlier lines of therapy, exploring combination treatment regimens, and expanding applications to other Claudin18.2-positive solid tumors such as pancreatic cancer and biliary tract cancer.

Professor Lin Shen’s team at Peking University Cancer Hospital led the clinical studies of satri-cel. Professor Shen commented, “For patients with advanced G/GEJA who have failed multiple lines of prior therapy, previous treatment options were extremely limited and the prognosis was very poor. The approval of satri-cel provides us with a novel and effective therapeutic weapon. This product has brought clinically meaningful and significant benefits to such patients, with remarkable efficacy that is difficult to achieve with existing treatment modalities. More importantly, as a CAR-T product, satri-cel offers patients the opportunity to break free from the constraints of frequent hospital visits for treatment, achieving a leap from ‘prolonging survival’ to ‘improving quality of life.’ As the world’s first successfully marketed CAR-T therapy for solid tumors, satri-cel not only fills the gap in later-line treatment for advanced gastric cancer but also ushers in a new era of cellular therapy for solid tumors. This breakthrough lays a critical foundation for advancing frontline therapy and combination treatment strategies, and is expected to reshape the treatment landscape of gastric cancer and even gastrointestinal tumors. We believe that with the promotion of clinical application, this innovative therapy will illuminate new hope for life for the vast number of gastric cancer patients.”

Dr. Zonghai Li, Founder, Chairman of the Board, Chief Executive Officer, and Chief Scientific Officer of CARsgen, stated, “The approval and launch of satri-cel is an important milestone event marking the advancement of CAR-T cell therapy from hematologic malignancies to solid tumors. This would not have been possible without the trust and support of the patients and their families who participated in the clinical trials, the investigator teams, partners, regulatory agencies, and relevant departments. We will go all out to advance the clinical application and market access of satri-cel, ensuring that this innovative therapy benefits Chinese patients widely and in a timely manner. At the same time, we will strive to expand this product to more countries and regions to meet greater medical needs. In addition, we are also exploring first-line sequential therapy and postoperative adjuvant therapy for advanced gastric cancer, with the aim of helping more patients achieve deeper therapeutic benefits and even the possibility of cure.”

About Satri-cel

Satri-cel is an autologous CAR T-cell therapy product against the protein Claudin18.2 that is the first-in-class globally. Satri-cel targets the treatment of Claudin18.2-positive solid tumors. It was approved by the NMPA in June, 2026 for the treatment of Claudin18.2-positive, HER2-negative advanced gastric/ gastroesophageal junction adenocarcinoma (G/GEJA) in patients who have failed at least two prior lines of therapy, making it the world’s first approved CAR T-cell therapy product for solid tumors.

The Company is actively expanding satri-cel application in early-line treatment and perioperative treatment of cancer, including an ongoing Phase I clinical trial for pancreatic cancer adjuvant therapy in China (NCT05911217), an IIT for consolidation treatment following adjuvant therapy in patients with resected G/GEJA (NCT06857786) and an IIT for sequential therapy following first-line treatment for G/GEJA (NCT07179484).

About CARsgen Therapeutics Holdings Limited

CARsgen is a biopharmaceutical company focusing on developing innovative CAR T-cell therapies to address the unmet clinical needs including but not limited to hematologic malignancies, solid tumors and autoimmune diseases. CARsgen has established end-to-end capabilities for CAR T-cell research and development covering target discovery, preclinical research, product clinical development, and commercial-scale production. CARsgen has developed novel in-house technologies and a product pipeline with global rights to address challenges faced by existing CAR T-cell therapies. Efforts include improving safety profile, enhancing the efficacy in treating solid tumors, and reducing treatment costs, etc. CARsgen’s mission is to be a global biopharmaceutical leader that provides innovative and differentiated cell therapies for patients worldwide and makes cancer and other diseases curable.

Forward-looking Statements

All statements in this press release that are not historical fact or that do not relate to present facts or current conditions are forward-looking statements. Such forward-looking statements express the Group’s current views, projections, beliefs and expectations with respect to future events as of the date of this press release. Such forward-looking statements are based on a number of assumptions and factors beyond the Group’s control. As a result, they are subject to significant risks and uncertainties, and actual events or results may differ materially from these forward-looking statements and the forward-looking events discussed in this press release might not occur. Such risks and uncertainties include, but are not limited to, those detailed under the heading “Principal Risks and Uncertainties” in our most recent annual report and interim report and other announcements and reports made available on our corporate website, https://www.carsgen.com. No representation or warranty is given as to the achievement or reasonableness of, and no reliance should be placed on, any projections, targets, estimates or forecasts contained in this press release.

References

[1] World Health Organization (WHO). International Agency for Research on Cancer. Cancers Fact Sheet (Globocan 2022). Cancer Today (who.int). Last accessed 22-May-2024.

[2] International Agency for Research on Cancer. (2021). Stomach fact sheet. IARC Global Cancer Observatory.

[3] Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115-32.

[4] B. Han, R. Zheng, H. Zeng, S. Wang, K. Sun, R. Chen, et al. Cancer incidence and mortality in China, 2022. J Natl Cancer Center, 4 (1) (2024), pp. 47-53.

[5] Zhao, Lulu, et al. “Changing Landscape in Stage, Treatment and Survival of Gastric Cancer in China 1998–2022: Insights of 40,158 Patients from the National Gastric Cancer Cohort.” Cancer Letters, vol. 642, 2026, p. 218261. DOI: 10.1016/j.canlet.2026.218261.

[6] Qi C, Liu C, Peng Z, Zhang Y, Wei J, Qiu W, Zhang X, Pan H, Niu Z, Qiu M, Qin Y, Fang W, Ye F, Li N, Liu T, Liu A, Zhang X, Hu C, Zhang J, Cui J, Lin X, Wang S, Zhang J, Lin T, Qu X, Yuan X, Gong J, Li J, Gao W, Gai L, Wang Y, Yuan D, Li Z, Shen L. Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician’s choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial. Lancet. 2025 Jun 7;405(10494):2049-2060. doi: 10.1016/S0140-6736(25)00860-8. Epub 2025 May 31. PMID: 40460847.

Contact CARsgen
For more information, please visit https://www.carsgen.com/
Public Relations: PR@carsgen.com
Investor Relations: IR@carsgen.com 

State Grid Lintao Power Supply Company: Power Illuminates Millennia-Old Ceramic Charm, Craftsmanship Safeguards the Torch of Intangible Cultural Heritage

By
Advertorial Desk
-

DINGXI, China, June 22, 2026 /PRNewswire/ — The millennia-long ceramic art of Majiayao unfolds like poetry, nourished by the cultural heritage nurtured by the Taoshui River stretching a hundred li. As a vital booster for the inheritance of intangible cultural heritage, power lays a solid foundation for the growth of local cultural industries. Recently, State Grid Lintao Power Supply Company took proactive responsibility and delivered targeted energy support. Its staff conducted routine equipment inspections at Lintao Xinyuan Antique Pottery Development Co., Ltd., wholeheartedly safeguarding the steady development of the intangible cultural heritage industry and reviving traditional culture with consistent, reliable power supply.

Stable Power Guarantees Upgraded Development of Intangible Cultural Heritage Industries

Lintao Xinyuan Antique Pottery Development Co., Ltd. is a key local enterprise carrying forward the Majiayao pottery craftsmanship. Its entire production process relies on electrical machinery, including clay mixers, clay kneaders, wheel-throwing machines, trimming lathes and electric kilns. These complete sets of equipment impose stringent requirements on power quality and voltage stability. Particularly during firing in electric kilns, voltage fluctuations or unexpected power outages will easily disrupt temperature control inside kilns, resulting in mass scrapping of pottery works and irreversible economic losses for the enterprise.

The company provides exclusive one-on-one services via district managers and includes the pottery firm in the streamlined power service system for micro and small enterprises. Workers regularly visit the workshop to identify hidden electrical risks in power lines, switches and kiln facilities. A dedicated power guarantee mechanism for key customers has been established, featuring periodic equipment patrols and infrared temperature detection. Comprehensive emergency repair plans are refined to enable rapid response and expedited troubleshooting of sudden faults, fully securing stable operation of this intangible cultural heritage enterprise.

Power Accelerates the Construction of Cultural Venues

Beyond supporting the production of heritage crafts, the power company also fuels the development of cultural exhibition spaces. The Lintao Majiayao Culture Research & Exhibition Center serves as a core provincial and national platform for inheriting, displaying and promoting Majiayao intangible cultural heritage.

During the project’s construction phase, the company assigned dedicated staff to provide frontline customized services, listing the venue as a priority cultural livelihood project. It tailored a targeted power supply scheme and opened a green channel for power application procedures, streamlining approval steps and shortening processing cycles. The supporting power expansion project was finished 15 days ahead of schedule: two 500kVA dedicated transformers were newly installed, alongside high-voltage metering devices and intelligent switchgears, with 75 meters of dedicated power lines erected. These facilities form a robust power foundation for daily venue operation and cultural exhibitions.

Power Empowers Intangible Heritage, Ingenuity Passes Down Civilization

Moving forward, State Grid Lintao Power Supply Company will continue to deepen power services for cultural tourism and intangible heritage sectors while optimizing the business environment. With premium, efficient and dependable power support, the company will keep lighting the path of Majiayao cultural inheritance, allowing the thousand-year ceramic charm to shine brilliantly and endure perpetually in the new era.

1...266267268...6,516Page 267 of 6,516